Internet-Administered Smoking Cessation Treatment for Overweight and Obese Smokers

This study has been completed.
American Heart Association
Information provided by (Responsible Party):
Marney A. White, Yale University Identifier:
First received: November 11, 2010
Last updated: February 12, 2014
Last verified: February 2014

This project will be a randomized clinical trial testing the efficacy of an internet-administered smoking cessation treatment for overweight and obese smokers. Research on internet-administered behavioral treatments for smoking cessation has found that compared to control treatments (e.g., self-help materials), cessation rates in internet-administered treatments are significantly higher. Research testing the applicability of these treatments to overweight and obese individuals has not yet been conducted. Given that a substantial portion of smokers are also overweight and at elevated cardiovascular risk, there is a need for directed treatment efforts for this group. The current trial proposes to be the first to test the effectiveness of internet-administered smoking cessation treatment for overweight and obese (BMI≥25) smokers. Adult participants will be randomized to receive 12 weeks of internet-administered treatment consisting of either: a) standard smoking cessation treatment with general health education, or b) standard smoking cessation treatment with cognitive behavioral therapy (CBT) for weight concerns. Participants in both conditions will receive open-label treatment with the 21 mg transdermal nicotine patch.

Condition Intervention
Smoking Cessation
Drug: Nicotine patch

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Internet-Administered Smoking Cessation Treatment for Overweight and Obese Smokers

Resource links provided by NLM:

Further study details as provided by Yale University:

Primary Outcome Measures:
  • Smoking cessation (abstinence) [ Time Frame: Post-treatment (12-weeks) ] [ Designated as safety issue: No ]
    Continuous abstinence during the last 28 days of treatment, confirmed by biologically verified abstinence (CO level <10ppm)

Secondary Outcome Measures:
  • Weight change [ Time Frame: Post-treatment (12 weeks) ] [ Designated as safety issue: No ]
    % Weight change: (pre-treatment weight - post-treatment weight)/ pre-treatment weight

Enrollment: 54
Study Start Date: July 2010
Study Completion Date: November 2013
Primary Completion Date: November 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Cognitive Behavioral Treatment + Nicotine Replacement Drug: Nicotine patch
Transdermal Nicotine Replacement Therapy - 21 mg daily for 10 weeks
Active Comparator: Health Education + Nicotine Replacement Drug: Nicotine patch
Transdermal Nicotine Replacement Therapy - 21 mg daily for 10 weeks


Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Smoking 10 or more cigarettes per day
  • Regular access to the internet
  • BMI>=25

Exclusion Criteria:

  • Type I diabetes or Type II diabetes requiring medication
  • Alcohol or drug dependence within the past year
  • Females with current pregnancy or breastfeeding or intention to become pregnant within the next 12 months
  • Uncontrolled hypertension
  • Severe chronic obstructive pulmonary disease
  • Use of an investigational drug within 30 days or current participation in another clinical trial
  • Current use of tobacco products other than cigarettes or use of marijuana
  • Use of nicotine replacement therapy, clonidine, varenicline, bupropion, or nortriptyline within the month prior to enrollment
  • Use of a medication that might affect weight or appetite
  • History of allergic reactions to adhesives.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01259466

United States, Connecticut
Yale University School of Medicine
New Haven, Connecticut, United States, 06520
Sponsors and Collaborators
Yale University
American Heart Association
Principal Investigator: Marney A White, PhD, MS Yale University
  More Information

No publications provided

Responsible Party: Marney A. White, Assistant Professor of Psychiatry, Yale University Identifier: NCT01259466     History of Changes
Other Study ID Numbers: 1001006181
Study First Received: November 11, 2010
Last Updated: February 12, 2014
Health Authority: United States: Institutional Review Board

Keywords provided by Yale University:
Smoking cessation
Internet treatment

Additional relevant MeSH terms:
Body Weight
Signs and Symptoms
Autonomic Agents
Cholinergic Agents
Cholinergic Agonists
Ganglionic Stimulants
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Nicotinic Agonists
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs processed this record on August 31, 2015